Jupiter Wellness Initiates Clinical Study of CaniSun(TM) for the Treatment of Actinic Keratosis
Jupiter Wellness (Nasdaq: JUPW) has announced a clinical study for its CaniSun sunscreen, targeting actinic keratosis (AK), a prevalent skin condition. The study will involve 116 adults diagnosed with AK, assessing the efficacy of CaniSun in both treatment and prevention. Current AK treatments often involve surgeries or medications with side effects. CaniSun aims to provide a less invasive alternative, potentially reducing the risk of progression to squamous cell carcinoma. CEO Brian John highlights the opportunity to gather significant patient data from this evaluation.
- Initiating a clinical study for CaniSun demonstrates commitment to R&D.
- CaniSun may present a non-invasive treatment alternative for actinic keratosis.
- The study's potential to generate valuable patient data could support future product development.
- None.
JUPITER, FL / ACCESSWIRE / November 24, 2020 / Jupiter Wellness, Inc. (Nasdaq:JUPW), announced today they are initiating a clinical study of its CaniSun™ sunscreen lotion for the treatment of actinic keratosis (AK), the most common precancer that forms on the skin as a result of exposure to ultraviolet (UV) rays. The Skin Cancer Foundation, estimates 58 million Americans have one or more AK lesions which appear as raised, scaly discolored patches on sun exposed skin. Left untreated, approximately
The primary objective of this study is to evaluate Canisun as a treatment for Actinic Keratosis by evaluating the efficacy in both treatment and prophylaxis of patients. The clinical study will recruit an estimated 116 adults diagnosed with Actinic Keratosis and will be conducted by Applied Biology (Irvine, CA) The primary efficacy endpoint is the percentage of patients with complete clearance of AK lesions.
CaniSun is an over-the-counter (OTC) product, which in addition to being an effective sunscreen, may act as a prophylactic treatment to prevent AK from occurring and/or to inhibit its progression into squamous cell carcinoma (skin cancer). Current treatment protocol for AK is surgical removal and/or medication. Treatments on the market include the prescription cream Imiquimod, an immune response modifier; however, such creams may cause adverse side effects including intense local inflammation. CaniSun's potential efficacy may position it as an alternative therapy.
"I am excited to work with Applied Biology in the clinical evaluation of Canisun, which may have the potential to offer relief from this side-effect to patients exposure to UV rays" said Brian John CEO of Jupiter Wellness. "Initiating this AK study represents an important opportunity for Jupiter Wellness to obtain patient data and evaluate any potential benefits of our sunscreen products".
About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a developer of cannabidiol (CBD) based medical therapeutics and wellness products. The Company's clinical pipeline of CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its CaniSun™ sunscreen and other wellness brands.
For additional information, please visit www.JupiterWellnessInc.com. The Company's public filings can be found at www.Sec.gov.
Safe Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@JupiterWellnessInc.com
SOURCE: Jupiter Wellness, Inc.
View source version on accesswire.com:
https://www.accesswire.com/618204/Jupiter-Wellness-Initiates-Clinical-Study-of-CaniSunTM-for-the-Treatment-of-Actinic-Keratosis
FAQ
What is the purpose of the clinical study for CaniSun by Jupiter Wellness?
How many participants will be involved in the CaniSun clinical study?
What is actinic keratosis and its significance?
What are the expected outcomes of the CaniSun study?
What alternative treatments exist for actinic keratosis?
